Want to see HURA full AI Analyst Report?
Top Page
TuHURA Biosciences
(NASDAQ:HURA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.00
▼(-1.96% Downside)
Action:Reiterated
Date:09/16/26
The score is primarily constrained by weak financial performance (no revenue, widening losses, and significant ongoing cash burn), which elevates financing and dilution risk. Technicals also lean bearish with price below key moving averages and a negative MACD. Corporate events provide some support via credit facility access, but are offset by continued dependence on external funding and an expanded equity inducement plan; valuation offers little support given the negative P/E and no dividend.
Positive Factors
Clinical pipeline advancement
FDA clearance allows TuHURA to advance TBS-2025 into a Phase 1b study for patients with relapsed or refractory mutNPM1 AML, an area described as having unmet medical need. This expands clinical validation opportunities and could support later development if responses are encouraging.
Negative Factors
No commercial revenue
Zero reported revenue confirms that TuHURA remains pre-commercial and has not yet demonstrated product-market commercialization or internally generated sales. Until a candidate reaches approval and launch, the business must fund development without an operating revenue base to absorb its expenses.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline advancement
FDA clearance allows TuHURA to advance TBS-2025 into a Phase 1b study for patients with relapsed or refractory mutNPM1 AML, an area described as having unmet medical need. This expands clinical validation opportunities and could support later development if responses are encouraging.
Read all positive factors
TuHURA Biosciences (HURA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$131.91M
Dividend YieldN/A
Average Volume (3M)192.49K
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue GrowthN/A
EPS Growth84.80%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.54
Shares Outstanding63,726,616
10 Day Avg. Volume200,461
30 Day Avg. Volume192,492
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.31
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside341.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)N/A
TuHURA Biosciences Business Overview & Revenue Model
Company Description
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by w...
TuHURA Biosciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -23.47K | 0.00 | 0.00 | -55.00K | -60.00K | -60.00K |
| EBITDA | -29.41M | -29.36M | -17.43M | -8.27M | -14.59M | -21.97M |
| Net Income | -30.63M | -30.06M | -21.68M | -8.32M | -14.65M | -22.66M |
Balance Sheet | ||||||
| Total Assets | 31.75M | 27.35M | 19.97M | 4.36M | 15.20M | 6.40M |
| Cash, Cash Equivalents and Short-Term Investments | 995.98K | 3.62M | 12.66M | 3.67M | 14.25M | 5.55M |
| Total Debt | 407.02K | 700.02K | 202.54K | 2.34M | 138.22K | 644.07K |
| Total Liabilities | 13.25M | 6.42M | 5.37M | 5.92M | 2.89M | 7.15M |
| Stockholders Equity | 18.50M | 20.93M | 14.59M | -1.56M | 12.30M | -747.82K |
Cash Flow | ||||||
| Free Cash Flow | -29.90M | -27.71M | -14.79M | -12.03M | -7.54M | -6.57M |
| Operating Cash Flow | -29.69M | -27.63M | -14.73M | -11.95M | -7.51M | -6.56M |
| Investing Cash Flow | -213.67K | -1.34M | -6.05M | -1.30M | -36.28K | -3.28K |
| Financing Cash Flow | 22.39M | 19.93M | 29.77M | 2.66M | 16.25M | 7.04M |
TuHURA Biosciences Technical Analysis
Positive
2.04
Price Trends
2.13
Negative
2.23
Negative
1.85
Positive
Market Momentum
-0.01
Negative
49.52
Neutral
32.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HURA, the sentiment is Positive. The current price of 2.04 is below the 20-day moving average (MA) of 2.08, below the 50-day MA of 2.13, and above the 200-day MA of 1.85, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 49.52 is Neutral, neither overbought nor oversold. The STOCH value of 32.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HURA.
TuHURA Biosciences Risk Analysis
TuHURA Biosciences disclosed 62 risk factors in its most recent earnings report. TuHURA Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TuHURA Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $446.65M | 3.66 | -38.12% | ― | 30.47% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $90.76M | -5.00 | -50.17% | ― | ― | 70.27% | |
46 Neutral | $131.91M | -3.89 | -154.32% | ― | ― | 84.80% | |
44 Neutral | $114.77M | -1.05 | -1005.80% | 0.36% | -100.00% | 54.89% | |
43 Neutral | $7.04M | -0.16 | -329.08% | ― | ― | -19.07% | |
42 Neutral | $91.33M | -2.68 | -171.19% | ― | ― | 83.55% |
* Healthcare Sector Average
HURA
TuHURA Biosciences
2.10
-0.44
-17.32%
AGEN
Agenus
9.93
6.03
154.62%
INO
Inovio Pharmaceuticals
1.22
-1.15
-48.52%
SKYE
Skye Bioscience
1.61
-32.47
-95.28%
BMEA
Biomea Fusion
1.33
-0.76
-36.36%
CGTX
Cognition Therapeutics
0.96
-0.55
-36.42%
TuHURA Biosciences Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
TuHURA Biosciences Adopts 2026 Inducement Equity Plan
Positive
Sep 16, 2026
On September 10, 2026, TuHURA Biosciences’ board adopted a 2026 Inducement Equity Incentive Plan designed to grant equity awards to new employees as a material inducement to join the company or its subsidiaries. The plan reserves 5,000,000 s...
Business Operations and StrategyPrivate Placements and Financing
TuHURA Biosciences draws additional funds from credit facility
Positive
Sep 4, 2026
TuHURA Biosciences, Inc. previously entered into a revolving credit facility with Parkview Holdings One LLC on April 21, 2026, providing up to $50 million in loan availability and maturing on April 21, 2031. On September 2, 2026, the company drew ...
Business Operations and StrategyPrivate Placements and Financing
TuHURA Biosciences Expands Use of Revolving Credit Facility
Positive
Aug 21, 2026
On April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC establishing a revolving credit facility of up to $50 million that matures on April 21, 2031. On August 20, 2026, the company drew an addition...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
TuHURA Biosciences Reports Results of 2026 Annual Meeting
Positive
Aug 19, 2026
On August 18, 2026, TuHURA Biosciences held its 2026 Annual Meeting, where a quorum of stockholders representing 43 million shares participated in key governance decisions. Shareholders elected six directors to serve until the 2027 Annual Meeting,...
Business Operations and StrategyPrivate Placements and Financing
TuHURA Biosciences Expands Use of Revolving Credit Facility
Positive
Aug 13, 2026
On April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC for a revolving credit facility of up to $50 million, maturing on April 21, 2031. The agreement provides the company with flexible access to c...
Business Operations and StrategyPrivate Placements and Financing
TuHURA Biosciences Expands Revolving Credit Facility Utilization
Positive
Jul 29, 2026
On April 21, 2026, TuHURA Biosciences, Inc. entered into a revolving credit facility with Parkview Holdings One LLC that provides up to $50 million in loan availability and matures on April 21, 2031. On July 28, 2026, the company drew an additiona...
Business Operations and StrategyPrivate Placements and Financing
TuHURA Biosciences Expands Use of Revolving Credit Facility
Positive
Jul 7, 2026
On April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC that established a revolving credit facility of up to $50 million, maturing on April 21, 2031. This long-term financing arrangement is designe...
Regulatory Filings and ComplianceShareholder Meetings
TuHURA Sets 2026 Virtual Annual Meeting, Proposal Deadlines
Neutral
Jun 17, 2026
TuHURA Biosciences’ board has set August 18, 2026, as the date for the company’s 2026 Annual Meeting of Stockholders, which will be held virtually, shifting it more than 30 days from the June 23, 2025 special meeting that served in lie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.